Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07226713
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Pacritinib is an oral drug which will be taken daily at a dose of 200 mg twice a day (BID).

Study Details

This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site within 30 days of treatment that demonstrates positive STAT5 activation status

Key Dates

First listed
Nov 10, 2025
Start date
Sep 3, 2026
Status verified
Sep 2026
Primary completion
Mar 1, 2029
Completion
Mar 1, 2031

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    Pacritinib is an oral drug.

Primary Outcome Measure

Progression-free Survival [ Time Frame: Six months ]

Central Contacts

  • Medical College of Wisconsin Cancer Center Clinical Trials Office
    866-680-0505
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert & the Medical College of WisconsinMilwaukeeWisconsin53226
Deepak Kilari, MD
[email protected]
414-805-4600
Deepak Kilari, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Milwaukee, WI

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials
By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Froedtert & the Medical College of Wisconsin· Milwaukee, WI

Related Studies